Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A phase III clinical trial compared eribulin mesylate to capecitabine in women with previously treated metastatic breast cancer, showing a trend towards improved overall survival. The median overall survival was 15.9 months for eribulin and 14.5 months for capecitabine.
Researchers found that some women with HER2 negative breast cancer may still benefit from anti-HER2 drugs due to undetected mutations. The study identified 25 patients with HER2 mutations without amplification, and most responded well to treatment. A phase II clinical trial is now underway to test the effectiveness of these treatments.
A groundbreaking clinical trial reveals that women with estrogen receptor-positive breast cancer who take tamoxifen for 10 years have a lower risk of recurrence and mortality rate compared to those taking the drug for 5 years. This new finding may prompt patients to reconsider their treatment options, particularly premenopausal women.
The study, led by Peter Jones, identified specific genes that must be turned off for cancer cells to survive. The findings provide a new target for cancer treatments and may lead to more effective medicine.
Research by Nemours and University of Delaware teams found improved quality of life and survival in leukemia patients treated with nanoparticle-based drug delivery. The approach reduces side effects and allows precise targeting of cancer cells, offering a promising alternative to traditional chemotherapy.
A new drug demonstrated dramatic effects on prostate cancer that had spread to the bone, with two-thirds of patients showing improvements on their bone scans. Additionally, 67% of patients with bone pain reported improved pain control after treatment with cabozantinib.
The growing US population and increased life expectancy necessitate new approaches to prostate cancer treatment. Researchers are exploring targeted therapies, immunotherapy, and precision radiation targeting to improve treatment outcomes for older patients.
A Mayo Clinic-led study found that patients with ovarian cancer who took metformin for their diabetes had a better survival rate than those who did not take the medication. After five years, 67% of metformin-takers were still alive compared to 47% of non-takers.
Researchers found that ovarian cancer patients who took metformin lived significantly longer than those who did not, with a 3.7 times increased survival rate after accounting for other factors. The study suggests metformin may be considered for prevention or treatment of ovarian cancer.
The American Society of Clinical Oncology (ASCO) has released its annual report on the top cancer advances of 2012, showcasing significant developments in precision medicine and targeted treatments. The report highlights seven new FDA approvals for anticancer agents, including therapies for breast and prostate cancers.
Researchers identified a transporter molecule on the surface of cancer cells that can take in a toxic substance, allowing it to kill cancer cells. This discovery could lead to more targeted and effective cancer treatments.
Researchers have found that targeting resistant lung cancer 'pockets' with focused radiation can prolong disease control in patients who initially respond to crizotinib or erlotinib. This approach showed significant benefits in patients whose cancers progressed in the brain, where the drugs are less effective.
Researchers have discovered how two proteins regulate telomeres, the protective caps on chromosome ends. The POT-1/TTP-1 complex promotes telomerase activity, a key target for anti-cancer drugs.
A phase I clinical trial has shown that ponatinib is highly active against patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma who have developed resistance to standard treatments. The study's findings suggest that ponatinib will expand the therapeutic armamentarium for these patients.
Researchers at UNC and Harvard have discovered a new alternative mechanism for activating the Ras protein, which plays a crucial role in cellular growth control. The discovery, published in Nature Structural and Molecular Biology, shows that modification of Ras with ubiquitin can activate it, leading to cancer formation.
Researchers at Huntsman Cancer Institute have discovered a new drug with high potential to treat Ewing sarcoma by targeting the EWS/FLI protein. The study found that an enzyme called lysine specific demethylase (LSD-1) interacts with EWS/FLI to turn off gene expression in Ewing sarcoma.
Scientists at Karolinska Institutet have found that IGF-1 blockers are only partially effective because they stimulate the MEK channel, allowing cancer cells to survive. Researchers propose a combination therapy using MEK inhibitors and IGF-1 blockers to overcome this issue
Researchers have identified telomerase as a cause of chronic inflammation in human cancers, a key underlying factor for many diseases. Developing drugs to target this enzyme may lead to novel treatments that alleviate common ailments such as cancer and diabetes.
A new targeted drug, regorafenib, has demonstrated its ability to control metastatic gastrointestinal stromal tumor (GIST) in patients who have become resistant to all existing therapies. The treatment improved disease control and survival rates for nearly four months longer than placebo.
A study identified a biomarker that can predict responses to cancer drugs and offers a way to treat drug-resistant tumors. The researchers discovered that inhibition of MED12, a gene mutated in cancers, causes drug resistance by enhancing signaling through the TGF-beta receptor.
Researchers have identified an enzyme used in nature to produce powerful chemicals from catnip, which could be used to create a more affordable and effective cancer treatment. The discovery also has potential applications in agriculture, as the enzyme's product can disrupt aphid breeding cycles or repel them from crops.
Regorafenib has shown significant promise in treating bowel cancer and gastrointestinal stromal tumors (GISTs) after standard treatments fail. Patients receiving regorafenib experienced improved overall survival rates and delayed progression compared to placebo.
Researchers at the University of New South Wales have developed a non-toxic nanoparticle that can deliver nitric oxide to specific cancer cells, reducing chemotherapy doses by a factor of five. This could lead to improved treatment outcomes and reduced side effects for neuroblastoma patients.
A UAlberta researcher has developed 'homing beacon drugs' that selectively kill cancer cells while sparing healthy ones. These smart drugs use nano-technology to identify cancer cells based on a unique protein found only in them, allowing for targeted treatment and potential reduction in side effects.
A phase 3 study published in the New England Journal of Medicine suggests there are benefits to both blood and marrow stem cell transplants, but no significant survival differences were found. Researchers from John Theurer Cancer Center played a key role in this groundbreaking study.
Researchers found that local ablative therapy and continuation of targeted drugs can prolong disease control by up to 6.2 months in patients with EGFR mutations or ALK rearrangements. The study's findings suggest a new approach to treating NSCLC after progression, particularly for patients with oligoprogressive disease.
Scientists at the University of Nottingham have discovered that cordycepin, a compound found in rare parasitic fungi, has potential as an anti-inflammatory drug. The study shows that cordycepin reduces inflammatory gene products in airway smooth muscle cells, making it a potential treatment for asthma and other inflammatory conditions.
Researchers identified PUMA, NOXA, and TRB3 as executors of glutamine-starved cells in Myc-mutant cells. The team showed that drugs targeting these proteins induced cell death in assays using neuroblastoma cells and inhibited tumor growth in transgenic mice.
Researchers found that inhibiting PI3-kinase can convert BRCA-proficient triple-negative breast cancers into BRCA-deficient ones, making them sensitive to PARP inhibitors. This combination treatment showed promising results in preclinical studies and is now being tested in a clinical trial.
Researchers identified 70 genetic mutations in Burkitt lymphoma tumors, including a new mutation that accelerates tumor growth. The findings could lead to the development of new treatments or targeted therapies for cancer patients.
Researchers have identified a specific cellular mechanism that may help overcome endocrine therapy-resistance in patients with estrogen-positive breast cancers. A novel molecular 'crosstalk' point between estrogen and HER2 signaling pathways has been found to drive tamoxifen resistance, according to new findings.
A combination of an anti-HER2 drug and an angiogenesis inhibitor significantly improves survival in a mouse model of brain metastatic breast cancer. The treatment extends patient survival by slowing the growth of brain tumors, making it a promising approach for patients with HER2-positive breast cancer who develop brain metastases.
Rice University chemist Zachary Ball and collaborators aim to create a drug that's effective against an 'undruggable' protein by using metal-based pins. They're attempting to answer whether new technologies can inhibit traditionally undruggable target molecules, including transcription factors required for cancer.
A study by University of Texas M.D. Anderson Cancer Center reveals that doxorubicin's cardiotoxicity is linked to the Top2b enzyme, which drives DNA damage and affects heart muscle metabolism. The discovery could lead to a simple blood test to predict sensitivity to the drug.
Researchers at UC Davis have developed a novel drug delivery system using nanoparticles that targets bladder cancer cells, allowing for higher doses of chemotherapy while reducing side effects. The system also enables diagnostic imaging, offering potential benefits for advanced bladder cancer treatment and management.
A comprehensive review of herbal and dietary supplement interactions reveals potentially harmful drug combinations, particularly among those with central nervous or cardiovascular systems. The study emphasizes the need for increased awareness and monitoring to mitigate risks.
Researchers at CU-Boulder have discovered a novel target for anti-cancer drug development by targeting the telomerase enzyme at the ends of chromosomes. This approach may provide an effective solution to the complex problem of cancerous cells. By blocking the telomerase enzyme, the growth of cancerous cells can be prevented.
Researchers found that Avastin increases survival in around 10-15% of bowel cancer patients by targeting the growth-promoting VEGF165 protein. Patients with lower levels of VEGF165b benefited from the treatment, while those with higher levels saw no improvement.
A study on histone modification could lead to targeted drugs for cancer treatment. Dr. Osley's research focuses on how ubiquitin attaches to H2B and its impact on DNA copying, potentially targeting quiescent cancer cells.
Researchers at Penn are developing programs to help people change high-risk behaviors, such as smoking and overeating, by enhancing the brain's cognitive control system. The study aims to assess the effects of neurocognitive training on decision-making processes and their impact on cancer risk.
Researchers found a daily multivitamin reduced the risk of total cancer by 8% in men over 50. The study also showed an apparent reduction in cancer deaths among those taking a multivitamin.
Researchers at Duke University Medical Center have identified new subtypes of gastric cancer linked to environmental factors. The study's findings suggest that these subtypes may be targeted with specific therapies, improving treatment outcomes for the second leading cancer killer worldwide.
A recent study found that nearly 4 out of 10 lesbians are not routinely screened for cervical cancer, highlighting the need for effective communication with healthcare providers. The study suggests that open communication between patients and providers can significantly increase screening rates among this population.
Researchers at the University of Minnesota have developed a new drug called Minnelide to target and destroy tumor cells in pancreatic cancer. The drug works by inhibiting heat shock protein HSP 70, which aids tumor cell growth, effectively disintegrating the cancer.
Researchers at Dana-Farber Cancer Institute have successfully shut down breast cancer and leukemia in mice by targeting abnormal proteins that control cell growth. The study found that inhibiting cyclin D1 or D3 proteins halts cancer growth, while normal cells remain unaffected.
Researchers have discovered that anti-cancer drugs can induce the growth and repair of muscle tissue by activating a specific cell-signalling pathway. This process involves the fusion of muscle cells to create new muscle fibres or repair damaged fibres.
Scientists at UC Santa Barbara aim to create a synthetic patch of fresh cells to replace malfunctioning ones in the eyes, treating age-related macular degeneration. The Garland Initiative, funded by philanthropist Bill Bowes, will advance regenerative bioengineering and cellular therapies for diabetic retinopathy.
Researchers have identified a novel signalling pathway controlling cellular energy metabolism, independent of the known hedgehog pathway. This discovery suggests that substances targeting this pathway could provide an easy and safe adjunct therapy for diabetes and obesity, resolving complications induced by cancer treatments.
A new study found that most parents of children are dissatisfied with the way clinicians communicate about suspected adverse drug reactions. Parents were unsure whether a child's reaction to a drug affected future use of the medicine, but those whose children had cancer expressed confidence in their clinicians' explanations.
Two USC research groups awarded $2.38M and $220K to study epigenetic drivers of cancer and how NSAIDs prevent colorectal cancer. A third group aims to develop new drugs to inhibit 'undruggable' target molecules.
A recent study from York University found that drugs approved through Health Canada's accelerated review process are more likely to be withdrawn or earn serious safety warnings than those undergoing standard reviews. This is due to the faster review process potentially missing serious safety issues.
Researchers have designed a blood test that can detect aggressive prostate cancers by analyzing the pattern of gene activity in blood cells. The test, which reads genetic changes like a barcode, can accurately identify patients with advanced prostate cancers and predict their survival time.
Research from UAlberta finds that overweight and obese children aged 12-19 are 59% more likely to take prescription medication. This trend contributes to higher health-care costs for treating childhood obesity.
The CU Cancer Center is conducting a Phase I clinical trial of OMP-54F28, a drug that targets cancer stem cells and the Wnt signaling pathway. The trial aims to assess the safety and efficacy of the agent in patients with advanced solid tumor cancers.
Researchers discovered microbial-dependent mechanisms that fuel cancer growth, exploiting immune cells and disrupting tissue homeostasis. Inhibiting inflammation may reduce cancer risk by up to 45%.
Scientists at USC have discovered a new type of drug that works by targeting Protein Disulfide Isomerase (PDI) in ovarian cancer cells. The drug, PACMA31, has shown promise in reducing the number of doses needed and making it effective for patients with resistant cancer.
Researchers at Wake Forest University have designed a targeted therapy that delivers a sneak attack on breast cancer cells, similar to a Trojan horse. The new platinum-based molecule has shown promising results in treating non-small cell lung cancer and pancreatic cancer, with potential applications for breast cancer treatment.
Evidence suggests aspirin may lower colorectal cancer risk by 24% and mortality rates by 35%, but concerns remain about side effects. The ESMO Congress debates whether aspirin should be used for chemoprevention of colorectal adenoma/cancer.
Researchers at the University of Texas Health Science Center San Antonio have discovered a potential cure for triple-negative breast cancer. They found that microRNAs can sensitize drug-resistant tumors to chemotherapy drugs like paclitaxel, reducing side effects and improving treatment outcomes.
Cancer drugs are administered sequentially or in combination, creating a virtual monopoly for each drug. Value-based pricing is a potential solution to address the high cost of cancer therapy.